Healthcare / BiotechnologyKOSDAQ
$3050.00
-125.00 (-3.94%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-25.0B · quality 64.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
6/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$85.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-48.6%
↓Gross Margin
-20.2%
↓Debt/Equity
0.71
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-24.0%
FCF CAGR
—
FCF margin
-79.0%
FCF / Net income
0.59x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $20.16B · net income $-26.83B · FCF $-15.92B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $20.16B | $20.16B | $28.76B | $33.66B | $45.88B |
| Net Income | $-26.83B | $-26.83B | $-26.25B | $-17.67B | $-2.26B |
| EBITDA | $-20.95B | $-20.95B | $-22.04B | $-9.03B | $13.46B |
| EPS | -903.00 | -903.00 | -944.11 | -703.04 | -435.51 |
| Gross Margin | -20.2% | -20.2% | -3.9% | 10.4% | 33.2% |
| Operating Margin | -105.3% | -105.3% | -76.6% | -58.5% | -13.8% |
| Net Margin | -133.1% | -133.1% | -91.3% | -52.5% | -4.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.71 | 0.71 | 0.96 | 1.67 | 0.48 |
| Current Ratio | 0.28 | 0.28 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-15.92B | $-15.92B | $-44.16B | $-24.97B | $-18.19B |
| Returns | |||||
| ROE | -48.6% | -48.6% | -54.0% | -90.2% | -5.8% |
| Valuation | |||||
| EV/EBITDA | — | — | — | — | 16.56 |
| P/B | 1.64 | 1.64 | 2.46 | 9.03 | 5.35 |
| Growth & Yield | |||||
| Revenue Growth | -29.9% | -29.9% | -14.5% | -26.6% | — |
| EPS Growth | 4.4% | 4.4% | -34.3% | -61.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-1.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-944.11 → -903.00
Residual
-1.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.